Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Procysbi Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Procysbi Prior Authorization Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Procysbi for commercial members. Approval requires an eligible indication, applicable age support, prior Cystagon history or qualifying intolerance or contraindication, specialist involvement, and no FDA-labeled contraindication to Procysbi.

    Policy Summary
    PayerPrime Therapeutics
    PolicyProcysbi Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDecember 15, 2025
    Next Review DateN/A
    Key ActionEstablish an eligible indication, qualifying Cystagon history or exception, specialist involvement, and no FDA-labeled contraindication to Procysbi.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsMaximum approval length
    25, 75, 300 mgListed Procysbi strengths
    AHFS or DrugDex 1/2aAccepted compendia evidence

    Coverage Criteria

    Initial therapy approval criteria

    Policy Summary
    PayerPrime Therapeutics
    PolicyProcysbi Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDecember 15, 2025
    Next Review DateN/A
    Key ActionEstablish an eligible indication, qualifying Cystagon history or exception, specialist involvement, and no FDA-labeled contraindication to Procysbi.
    SourceLink
    On This Page
    Coverage CriteriaProvider RequirementsDefined TermsInitial AuthorizationStep Therapy Requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Target agents will be approved when ALL of the following are met:

    All approval requirements

    • Eligible indication

      • The patient has a diagnosis of nephropathic cystinosis.
      • The patient has another FDA-labeled indication for the requested agent and route of administration.
      • The patient has an indication supported in compendia for the requested agent and route of administration.

        Allowed compendia: AHFS or DrugDex with level 1 or 2a evidence.

    • Age requirement for an FDA-labeled indication

      • Age support

        • The patient's age is within FDA labeling for the requested indication.
        • There is support for using the requested agent for the patient's age for the requested indication.
    • Cystagon history or exception

      • The patient tried Cystagon and had an inadequate response.
      • The patient has an intolerance or hypersensitivity to Cystagon that is not expected to occur with the requested agent.
      • The patient has an FDA-labeled contraindication to Cystagon that is not expected to occur with the requested agent.
    • Specialist involvement

      • The prescriber is a specialist in the area of the patient's diagnosis, such as a nephrologist, or the prescriber has consulted with a specialist in that area.
    • No Procysbi contraindication

      • The patient does not have any FDA-labeled contraindications to the requested agent.

    Approval is excluded when the patient has any FDA-labeled contraindication to the requested Procysbi agent.

    Provider Requirements

    Prior Authorization

    Clinical Approval Requirements

    Approve the requested agent when the patient has an eligible indication, meets applicable age-support requirements, satisfies the separate Cystagon prerequisite, has specialist involvement, and has no FDA-labeled contraindication to the requested agent.

    • Eligible indication: nephropathic cystinosis; another FDA-labeled indication for the requested agent and route; or an indication supported by AHFS or DrugDex evidence level 1 or 2a for the requested agent and route.
    • For an FDA-labeled indication, the patient's age must be within FDA labeling or there must be support for use in the patient's age group for that indication.
    • The prescriber must be a specialist in the area of the diagnosis, such as a nephrologist, or must have consulted with an appropriate specialist.
    • The patient must not have any FDA-labeled contraindication to the requested agent.
    • Length of approval: 12 months.
    Step Therapy

    Cystagon Prerequisite

    Document that the patient tried immediate-release cysteamine (Cystagon) and had an inadequate response, or that Cystagon cannot be used because of a qualifying exception.

    • Inadequate response after a trial of Cystagon.
    • Intolerance or hypersensitivity to Cystagon that is not expected to occur with the requested agent.
    • An FDA-labeled contraindication to Cystagon that is not expected to occur with the requested agent.
    Denial Risk

    Failure to Meet Clinical Criteria

    Coverage may be denied when the patient does not have an eligible indication or when required supporting criteria are not met. This includes failure to establish age support when an FDA-labeled indication applies, failure to meet the Cystagon prerequisite, lack of required specialist involvement, or the presence of an FDA-labeled contraindication to the requested agent.

    • Deny when the indication is not nephropathic cystinosis, another FDA-labeled indication for the requested agent and route, or an indication supported by AHFS or DrugDex evidence level 1 or 2a.
    • Deny when the required age or age-support evidence is absent for an FDA-labeled indication.
    • Deny when there is no qualifying inadequate response, intolerance, hypersensitivity, or contraindication related to Cystagon.
    • Deny when specialist involvement is not established or when the requested agent has an FDA-labeled contraindication.

    Defined Terms

    Definitions
    DefinitionImmediate-release cysteamine

    Initial Authorization

    Initial authorization

    Procysbi will be approved when all listed criteria are met:

    Procysbi initial authorization

    • Eligible indication

      • The patient has a diagnosis of nephropathic cystinosis.
      • The patient has another FDA-labeled indication for the requested agent and route of administration.
      • The patient has an indication supported in compendia for the requested agent and route of administration.
    • Age requirement for an FDA-labeled indication

      • Age support

        • The patient's age is within FDA labeling for the requested indication.
        • There is support for using the requested agent for the patient's age for the requested indication.
    • Cystagon history or exception

      • The patient tried Cystagon and had an inadequate response.
      • The patient has an intolerance or hypersensitivity to Cystagon that is not expected to occur with the requested agent.
      • The patient has an FDA-labeled contraindication to Cystagon that is not expected to occur with the requested agent.
    • Specialist involvement

      • The prescriber is a specialist in the area of the patient's diagnosis, such as a nephrologist, or the prescriber has consulted with a specialist in that area.
    • No Procysbi contraindication

      • The patient does not have any FDA-labeled contraindications to the requested agent.

    Step Therapy Requirement

    StepRequired therapyQualifying exception
    1Try Cystagon (immediate-release cysteamine) before Procysbi and document an inadequate response.Prior Cystagon therapy is not required when the patient has an intolerance or hypersensitivity to Cystagon, or an FDA-labeled contraindication to Cystagon, and the issue is not expected to occur with Procysbi.